I am an associate attending physicist in the Department of Medical Physics. Since joining Memorial Sloan Kettering in 2013, my clinical and research efforts have been focused on building a clinical and academic program on the application of magnetic resonance imaging (MRI) in radiation oncology. I have been actively involved in developing radiotherapy simulation workflows for combined MR-CT and MR-only simulation as well as in the use of anatomical and functional MRI as biomarkers for assessing response to therapy. Our efforts have resulted in MSK being the first institution to clinically implement MR-only simulation for prostate radiotherapy, which is recognized internationally as being on the forefront of MR applications in radiotherapy. I now lead the clinical program in MR-guided adaptive radiotherapy on the Elekta 1.5T Unity MR-linac system, which was put into clinical use in early 2020.
I received my PhD from the University of Michigan, Ann Arbor, in 2006, and I was board certified in therapeutic medical physics by the American Board of Radiology in 2010. I am a member of various national and international task groups and working groups that continue to work towards developing guidelines and recommendations, as well as identifying gaps and unmet needs, on the use of MRI in radiation oncology.
View a full listing of Neelam Tyagi’s journal articles.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Neelam Tyagi discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
View all disclosures